Search
CRISPR Therapeutics AG
CRSPAdd to Watchlist
58.600USD
+2.040+3.61%
Market hours 09/21, 12:38（ET）
5.66BMarket Cap
LossP/E TTM
CRISPR Therapeutics AG (CRSP) Stock Price Target & Forecast
Analyst Rating
Based on 22 analysts giving stock ratings to CRISPR Therapeutics AG in the past month.
Buy
4 Strong Buy
8 Buy
10 Hold
0 Sell
0 Strong Sell
Target Price
85.765USD+49.61%
CRSP Analyst Recommendation Trends
In the current month, CRSP has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the last month is 85.765.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
5
5
7
7
7
7
8
8
9
9
10
10
10
10
10
10
12
11
11
11
11
11
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
22
22
26
26
29
29
29
29
CRSP Analyst Rating for Peer Comparison
Updated: Sep 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, CRSP EPS is projected to reach -1.034 in FY2026Q3, following reported EPS of -0.944 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.15
-1.22
-1.20
-1.03
-1.10
Actual
-1.37
-1.28
-0.94
--
--
Surprise
-18.77%
-4.53%
+21.13%
--
--
FAQs
What is CRISPR Therapeutics AG's expected revenue for the next quarter?
CRISPR Therapeutics AG's expected revenue is 9.52M.
What is CRISPR Therapeutics AG's price target?
Analysts forecast that CRISPR Therapeutics AG's price target is USD 85.76, with the highest forecast at USD 291.00 and the lowest forecast at USD 44.00.
How have CRISPR Therapeutics AGCRSP's recent earnings per share performed?
The market expectation was USD -0.94, while CRISPR Therapeutics AGCRSP's earnings per share (EPS) for the previous quarter was USD -1.28. EPS for the next quarter is expected at USD -1.03.
What is the analyst rating for CRISPR Therapeutics AG?
Based on the ratings of CRISPR Therapeutics AG's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.